Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06885034
Registration number
NCT06885034
Ethics application status
Date submitted
13/03/2025
Date registered
19/03/2025
Date last updated
15/09/2025
Titles & IDs
Public title
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
Query!
Scientific title
A Phase 1b/2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of GSK5764227 Alone and in Combination in Participants With Previously Treated Advanced Unresectable or Metastatic Gastrointestinal Solid Tumors
Query!
Secondary ID [1]
0
0
2025-520672-26
Query!
Secondary ID [2]
0
0
223675
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Gastrointestinal Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Other cancer types
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Cancer
0
0
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - GSK5764227
Experimental: CRC-A: GSK5764227 (Dose 1) -
Experimental: CRC-A: GSK5764227 (Dose 2) -
Experimental: CRC-B: GSK5764227 (Dose 3) -
Experimental: CRC-B: GSK5764227 (Dose 4) -
Experimental: PDAC: GSK5764227 (Dose 5) -
Treatment: Other: GSK5764227
GSK5764227 will be administered
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Confirmed Objective Response Rate (ORR)
Query!
Assessment method [1]
0
0
Confirmed ORR is defined as the proportion of participants who have achieved best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as assessed by investigator, according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Query!
Timepoint [1]
0
0
Up to approximately 22 months
Query!
Secondary outcome [1]
0
0
Unconfirmed ORR
Query!
Assessment method [1]
0
0
Unconfirmed ORR is defined as the proportion of participants who have achieved a BOR of CR or PR as assessed by investigator, according to RECIST 1.1.
Query!
Timepoint [1]
0
0
Up to approximately 37 months
Query!
Secondary outcome [2]
0
0
Duration of Response (DoR)
Query!
Assessment method [2]
0
0
DoR is defined as the time from the date of the first documented objective response (CR/PR as assessed by investigator according to RECIST 1.1) until the date of the first documented progressive disease (PD) or death, whichever is earlier.
Query!
Timepoint [2]
0
0
Up to approximately 37 months
Query!
Secondary outcome [3]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [3]
0
0
PFS (assessed by investigator), defined as the time from date of randomization (for participants in CRC-A and CRC-B) or the date of first dose study intervention for participants in PDAC until the earliest date of documented disease progression per RECIST 1.1 or death due to any cause.
Query!
Timepoint [3]
0
0
Up to approximately 37 months
Query!
Secondary outcome [4]
0
0
Number of participants with AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs) by severity
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Up to approximately 37 months
Query!
Secondary outcome [5]
0
0
Number of participants with AEs leading to dose modifications, discontinuation of study interventions or death
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Up to approximately 37 months
Query!
Secondary outcome [6]
0
0
Changes from baseline in vital signs: Temperature (degree Celsius)
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [7]
0
0
Changes from baseline vital signs: Respiratory rate (breaths per minute)
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [8]
0
0
Changes from baseline vital signs: Pulse rate (beats per minute)
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [9]
0
0
Changes from baseline vital signs: Blood pressure [millimetres of mercury (mmHg)
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [10]
0
0
Changes from baseline in hematology parameters: [White blood cell count (WBCs per microliter)
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [11]
0
0
Changes from baseline in hematology parameters: [Haemoglobin (Hgb) (grams per deciliter)
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [12]
0
0
Changes from baseline in hematology parameters:[Haematocrit (Proportion of red blood cells in blood)
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [13]
0
0
Changes from Baseline haematology parameter: [Red Blood Cell Count (RBC) (million cells per microliter)
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [14]
0
0
Changes from baseline haematology parameters: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per liter)
Query!
Assessment method [14]
0
0
Query!
Timepoint [14]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [15]
0
0
Changes from Baseline haematology parameter: Platelet count (cells per microliter)
Query!
Assessment method [15]
0
0
Query!
Timepoint [15]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [16]
0
0
Changes from baseline Clinical chemistry parameters: Total Protein, Albumin (Grams per deciliter)
Query!
Assessment method [16]
0
0
Query!
Timepoint [16]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [17]
0
0
Changes from baseline Clinical Chemistry parameters: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per liter)
Query!
Assessment method [17]
0
0
Clinical chemistry parameters such as Aspartate Aminotransferase (AST) / Serum Glutamic-Oxaloacetic Transaminase (SGOT), Alanine Aminotransferase (ALT)/ Serum Glutamic-Pyruvic Transaminase and (SGPT), Alkaline phosphatase (ALP) and Creatinine Phosphokinase (CPK) will be analysed
Query!
Timepoint [17]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [18]
0
0
Changes from baseline Clinical Chemistry parameters: Total Bilirubin and Direct Bilirubin, Glucose, Calcium, Potassium, Sodium, Magnesium, Urea Nitrogen or urea, and Creatinine (milligrams per deciliter)
Query!
Assessment method [18]
0
0
Query!
Timepoint [18]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [19]
0
0
Changes from baseline Clinical Chemistry parameters: Lactate dehydrogenase, Amylase and Lipase (units per liter)
Query!
Assessment method [19]
0
0
Query!
Timepoint [19]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [20]
0
0
Changes from baseline Clinical Chemistry parameters: Chloride (millimoles per liter)
Query!
Assessment method [20]
0
0
Query!
Timepoint [20]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [21]
0
0
Changes from baseline Clinical Chemistry parameters: Creatinine clearance (milliliters per minute)
Query!
Assessment method [21]
0
0
Query!
Timepoint [21]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [22]
0
0
Changes from baseline cardiac function: Electrocardiogram (ECG) (milliseconds)
Query!
Assessment method [22]
0
0
Query!
Timepoint [22]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [23]
0
0
Changes from baseline Eastern Cooperative Oncology Group performance status (ECOG-PS)
Query!
Assessment method [23]
0
0
Query!
Timepoint [23]
0
0
Baseline (Day 1) and up to approximately 37 months
Query!
Secondary outcome [24]
0
0
Maximum observed concentration (Cmax) of GSK5764227 (conjugated antibody) and GSK5757810 (small molecule toxin)
Query!
Assessment method [24]
0
0
Query!
Timepoint [24]
0
0
Up to approximately 37 months
Query!
Secondary outcome [25]
0
0
Time to reach Cmax (Tmax) of GSK5764227 (conjugated antibody) and GSK5757810 (small molecule toxin)
Query!
Assessment method [25]
0
0
Query!
Timepoint [25]
0
0
Up to approximately 37 months
Query!
Secondary outcome [26]
0
0
Area under the concentration-time curve (AUC) of GSK5764227 (conjugated antibody) and GSK5757810 (small molecule toxin)
Query!
Assessment method [26]
0
0
Query!
Timepoint [26]
0
0
Up to approximately 37 months
Query!
Secondary outcome [27]
0
0
Number of participants with Antidrug antibody (ADA) or Neutralizing Antibody (NAb)
Query!
Assessment method [27]
0
0
Query!
Timepoint [27]
0
0
Up to approximately 37 months
Query!
Secondary outcome [28]
0
0
Titers of ADA against GSK5764227
Query!
Assessment method [28]
0
0
Query!
Timepoint [28]
0
0
Up to approximately 37 months
Query!
Secondary outcome [29]
0
0
Number of participants with symptomatic AEs, by severity, as measured by Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Query!
Assessment method [29]
0
0
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes a library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE
Query!
Timepoint [29]
0
0
Up to approximately 37 months
Query!
Secondary outcome [30]
0
0
Level of bother of AEs as measured by Functional Assessment of Cancer Therapy - Item GP5 (FACT-GP5)
Query!
Assessment method [30]
0
0
The FACT-GP5 item is a single item from the FACT-G that assesses how bothersome the side effects of treatment are for cancer patients. The item has a 5-category response scale ranging from 0 to 4. Higher scores indicate a higher degree of AE bother.
Query!
Timepoint [30]
0
0
Up to approximately 37 months
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
• Is at least 18 or the legal age of consent in the jurisdiction in which the study is taking place years of age at the time of signing the informed consent form (ICF).
CRC Cohort
* Has histologically confirmed unresectable/, locally advanced or unresectable metastatic adenocarcinoma of the colon or rectum (histology defined by World Health Organization (WHO) classification).
* Must have received at least 1 and no more than 2 lines of systemic treatment for advanced colorectal cancer (CRC), with documented progression on most recent prior line of therapy.
* Must provide tumor tissue from a newly obtained fresh biopsy or an archival tumor tissue.
PDAC Cohort
* Has histologically or cytologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of the pancreas (histology defined by WHO classification).
* Must have received 1 and no more than 1 line of therapy for advanced PDAC, with documented progression.
* Should provide tumor tissue at screening, where available or medically feasible.
All Cohorts
* Has at least 1 target lesion per RECIST 1.1, as determined by the investigator.
* Is willing to use adequate contraception.
* Is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol.
* Has an ECOG performance status of 0 or 1.
* Has adequate organ function.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
Participants are excluded from the study if any of the following criteria apply:
* Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas [e.g., breast, cervix, bladder] that have been resected with no evidence of disease.
* Has had any major surgery within 28 days prior to randomization (CRC Cohort) or first dose of study intervention (PDAC Cohort).
* Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant.
* Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
* Has severe, uncontrolled or active cardiovascular disorders.
* Has serious or poorly controlled hypertension.
* Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose.
* Has serious infection within 4 weeks prior to the first dose.
* Known active infectious diseases requiring systemic treatment or known Human immunodeficiency virus (HIV).
* Has serious arteriovenous thromboembolic events (such as deep vein thrombosis, pulmonary embolism, etc.) within 3 months prior to the first dose.
* Has untreated brain or Central nervous system (CNS) metastases or brain/CNS metastases that have progressed.
* Has current active pneumonitis or any history of pneumonitis requiring steroids or immunomodulatory treatment within 90 days of planned [randomization] or any history of drug-induced pneumonitis.
* Has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screening.
* Has any active renal condition (e.g., infection, requirement for dialysis, or any other significant renal condition that could affect the participant's safety).
* Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to Grade 1 or to the baseline status preceding prior therapy.
* Has any serious and/or unstable medical or psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of informed consent, or compliance to the study procedures.
* Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.
* Has documented presence of Hepatitis B surface antigen (HBsAg) or HBcAb at screening or within 3 months prior to the first dose of study intervention.
* Has a positive Hepatitis C virus (HCV) antibody test result at screening or within 3 months prior to the first dose of study intervention.
* Has a positive HCV RNA test result at screening or within 3 months prior to the first dose of study intervention.
* Has received immunosuppressive agents within 30 days prior to first dose of study intervention (or requires long-term [30 days or longer]).
* Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload.
* Has received any live vaccine within 30 days of randomization (CRC Cohort) or before first dose of study intervention (PDAC Cohort).
* Is currently enrolled or has participated in any other clinical study involving an investigational study intervention or any other type of interventional medical research and/or has received treatment with any anticancer or investigational agent within 4 weeks prior to randomization.
* Is pregnant or breastfeeding.
* Is unable to adhere to the protocol defined SoA, including requirements for the Follow-up Period of the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
11/06/2025
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
23/06/2028
Query!
Actual
Query!
Sample size
Target
320
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Heidelberg
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [2]
0
0
3000 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Texas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Washington
Query!
Country [3]
0
0
Canada
Query!
State/province [3]
0
0
Ontario
Query!
Country [4]
0
0
Canada
Query!
State/province [4]
0
0
Quebec
Query!
Country [5]
0
0
Japan
Query!
State/province [5]
0
0
Hokkaido
Query!
Country [6]
0
0
Japan
Query!
State/province [6]
0
0
Osaka
Query!
Country [7]
0
0
Japan
Query!
State/province [7]
0
0
Tokyo
Query!
Country [8]
0
0
South Korea
Query!
State/province [8]
0
0
Seoul
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06885034
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
US GSK Clinical Trials Call Center
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
877-379-3718
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About\_GSK\_Patient\_Level\_Data\_Sharing\_Final\_13July2023.pdf
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Query!
Available to whom?
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06885034
Download to PDF